Interleukin 12 in the Acute Phase of the Immune Response after Excimer Laser Treatment.
IL-10
IL-12
IL-4
LASIK
PRK
corneal wound healing
excimer laser
tears
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
04 Jul 2023
04 Jul 2023
Historique:
received:
16
04
2023
revised:
20
06
2023
accepted:
30
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
The aim of the research was to investigate the differences in the concentrations of IL-12, IL-4, IL-10, and IFN-γ in tears after LASIK and PRK procedures. The study included 68 myopic eyes up to -3.0 D refractive spherical equivalent, divided into two groups: Group 1 LASIK ( IL-4 levels 1 h after treatment did not differ between LASIK and PRK ( IL-4 concentration shows a significantly higher value in the LASIK group than in the PRK group after 24 h. IL-10 and IL-12p70 levels increase one hour after surgery in both groups. After 24 h, the IL-10 levels remain elevated in the LASIK group, and the IL-12p70 levels remain elevated in the PRK group. Thus, LASIK and PRK procedures show different inflammatory dynamics.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The aim of the research was to investigate the differences in the concentrations of IL-12, IL-4, IL-10, and IFN-γ in tears after LASIK and PRK procedures.
MATERIALS AND METHODS
METHODS
The study included 68 myopic eyes up to -3.0 D refractive spherical equivalent, divided into two groups: Group 1 LASIK (
RESULTS
RESULTS
IL-4 levels 1 h after treatment did not differ between LASIK and PRK (
CONCLUSIONS
CONCLUSIONS
IL-4 concentration shows a significantly higher value in the LASIK group than in the PRK group after 24 h. IL-10 and IL-12p70 levels increase one hour after surgery in both groups. After 24 h, the IL-10 levels remain elevated in the LASIK group, and the IL-12p70 levels remain elevated in the PRK group. Thus, LASIK and PRK procedures show different inflammatory dynamics.
Identifiants
pubmed: 37445506
pii: jcm12134472
doi: 10.3390/jcm12134472
pmc: PMC10342327
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Exp Med. 1998 Sep 21;188(6):1039-46
pubmed: 9743522
Ophthalmic Res. 2008 Oct;40(6):315-21
pubmed: 18688174
Graefes Arch Clin Exp Ophthalmol. 2006 Mar;244(3):382-9
pubmed: 16091952
Br J Pharmacol. 2013 Mar;168(6):1341-54
pubmed: 23072440
Acta Ophthalmol. 2014 May;92(3):e170-84
pubmed: 23819758
Invest Ophthalmol Vis Sci. 2002 May;43(5):1445-9
pubmed: 11980859
Prog Retin Eye Res. 2012 Nov;31(6):527-50
pubmed: 22732126
Exp Eye Res. 2013 Dec;117:106-17
pubmed: 23891862
Curr Eye Res. 2008 Jul;33(7):525-44
pubmed: 18600485
Invest Ophthalmol Vis Sci. 2002 Sep;43(9):2897-904
pubmed: 12202508
J Cataract Refract Surg. 1997 Oct;23(8):1153-9
pubmed: 9368157
Nat Rev Immunol. 2003 Feb;3(2):133-46
pubmed: 12563297
Ocul Surf. 2003 Apr;1(2):53-65
pubmed: 17075633
Clin Ophthalmol. 2016 May 30;10:993-1000
pubmed: 27313444
Fortschr Ophthalmol. 1987;84(6):513-8
pubmed: 3436577
J Cataract Refract Surg. 2009 May;35(5):921-33
pubmed: 19393895
Prog Retin Eye Res. 2010 May;29(3):208-48
pubmed: 20100589
J Cataract Refract Surg. 2009 Feb;35(2):240-7
pubmed: 19185237
Clin Exp Ophthalmol. 2010 Mar;38(2):168-82
pubmed: 20398106
J Refract Surg. 2005 Nov-Dec;21(6):734-41
pubmed: 16331843
Immunity. 2019 Apr 16;50(4):851-870
pubmed: 30995503
Exp Eye Res. 2013 Dec;117:118-25
pubmed: 24012834
PLoS One. 2013 Oct 04;8(10):e76333
pubmed: 24124547
Cornea. 2005 Jul;24(5):509-22
pubmed: 15968154
Am J Ophthalmol. 2003 Sep;136(3):530-6
pubmed: 12967809
Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5692-5702
pubmed: 29101407
Surv Ophthalmol. 2013 Jan-Feb;58(1):11-25
pubmed: 23217585
Prog Retin Eye Res. 2001 Sep;20(5):625-37
pubmed: 11470453
Ocul Surf. 2019 Oct;17(4):753-762
pubmed: 31279064
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3591-8
pubmed: 20207959
J Cataract Refract Surg. 2000 Mar;26(3):426-31
pubmed: 10713241
Expert Opin Drug Saf. 2007 Jan;6(1):27-32
pubmed: 17181449